Esomeprazole Market to Reach $3.62 Billion by 2035

Esomeprazole market was valued at $2.01 billion in 2025 and is projected to reach $3.62 billion by 2035, growing at a CAGR of 6.05% during the forecast period (2026–2035). The increasing global burden of gastrointestinal disorders is significantly driving demand for proton pump inhibitors, particularly esomeprazole. Rising prevalence of gastroesophageal reflux disease (GERD), peptic ulcer disease, and acid-related disorders is strengthening the need for effective acid suppression therapies across both developed and emerging markets. Additionally, increasing consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) is contributing to higher incidence of gastric complications, further supporting sustained demand for esomeprazole-based treatments. According to the World Health Organization, gastrointestinal disorders are among the most commonly reported health conditions globally, with millions of individuals affected by acid-related diseases annually. Furthermore, the U.S. Food and Drug Administration highlights that prolonged NSAID use is a major contributor to gastric ulcer formation, increasing the requirement for preventive and therapeutic acid suppression medications. This growing patient pool, combined with expanding healthcare access, is reinforcing prescription volumes of esomeprazole across global healthcare systems.

Browse the full report description of “Esomeprazole Market Size, Share & Trends Analysis Report, By Product Type (Tablets, Capsules, Injectable (IV formulations), Oral Suspension / Sachets), By Application (Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, Zollinger–Ellison Syndrome, Helicobacter pylori Eradication (Combination Therapy), NSAID-induced Ulcers, Others (Acid-related disorders)), By Manufacturing Type (In-house Manufacturing, Contract Manufacturing (CMO/CDMO)), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/esomeprazole-market

European Healthcare Expansion Supporting Gastrointestinal Treatment Demand

In Europe, increasing healthcare expenditure and improved patient access to pharmaceutical treatments are supporting market growth. According to the European Commission, healthcare spending across member states has consistently increased, enabling better diagnosis and treatment of chronic gastrointestinal conditions. Additionally, aging demographics across Europe are contributing to higher incidence of GERD and ulcer-related diseases, which require long-term pharmacological management. Despite increasing adoption of preventive healthcare measures, the demand for proton pump inhibitors remains strong due to the chronic nature of acid-related disorders.

US Healthcare Utilization Trends Driving Prescription Growth

In the United States, high healthcare utilization rates are directly contributing to increased demand for esomeprazole. Data from the Centers for Disease Control and Prevention indicates that gastrointestinal symptoms account for a substantial number of outpatient visits annually. Increasing awareness regarding acid reflux and ulcer complications, along with widespread availability of prescription and over-the-counter proton pump inhibitors, is driving adoption across hospital and homecare settings. Additionally, the focus on preventive treatment for NSAID-induced ulcers is further strengthening market growth.

Innovation Leaders Strengthening the Esomeprazole Market

The key players in the esomeprazole market include AstraZeneca, Sandoz, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, among others. These companies are focusing on expanding generic portfolios, improving drug delivery formats, and strengthening supply chain capabilities to address growing global demand for proton pump inhibitors.

• In March 2026, Reddy's Laboratories announced the launch of India’s first DCGI-approved Semaglutide injection, ‘Obeda®’, for the treatment of Type 2 diabetes, strengthening its presence in the metabolic and chronic disease therapeutics segment.
• In February 2026, Dr. Reddy's Laboratories announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application (BLA) for a proposed interchangeable biosimilar to Abatacept, marking a key step toward expanding its biologics portfolio in immunology and autoimmune disease treatments.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Application
• Manufacturing Type
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – AstraZeneca, Sandoz, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Esomeprazole Market Segmentation

By Product Type (Formulation-Based)

• Tablets
• Capsules
• Injectable (IV formulations)
• Oral Suspension / Sachets

By Application

• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcer Disease
• Zollinger–Ellison Syndrome
• Helicobacter pylori Eradication (Combination Therapy)
• NSAID-induced Ulcers
• Others (Acid-related disorders)

By Manufacturing Type

• In-house Manufacturing
• Contract Manufacturing (CMO/CDMO)

Global Esomeprazole Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/esomeprazole-market